Carbon-ion radiotherapy (CIRT) is on the rise as a treatment choice for malignant tumor. Compared to conventional radiotherapy, particle beams have different physical and biological properties. Particle beam provides a low entry dose, deposits most of the energy at the endpoint of the flight path, and forms an asymptotic dose peak (the "Bragg peak"). Compared to protons, carbon with its larger mass decreases beam scattering, resulting in a sharper dose distribution border. We report a 50-year-old male who underwent CIRT without surgical resection on osteosarcoma of the mandible. After CIRT, the patient's pain was gone, and the malignant mass remained stable with accompanying necrosis. Nine months later, however, magnetic resonance imaging d...
[Purpose]To evaluate the safety and efficacy of carbon ion radiotherapy (C-ion RT) with 70.4 GyE for...
Carbon ion radiotherapy (CIRT) is a unique radiotherapy, which possesses well localized, and superio...
Carbon ion radiotherapy for bone and soft tissue sarcomas. T. Kamada, R. Imai, H. Tsujii, H. Tsuji, ...
Background and objectives: Osteoradionecrosis (ORN) of maxilla is a serious complication of radiothe...
Purpose To determine the recommend irradiation-dose of carbon ion radiotherapy and to evaluate the s...
Carbon ion radiotherapy (CIRT) is a unique radiotherapy, which possesses well localized and superior...
The first-line treatment for bone and soft-tissue tumors is inevitably surgery. Not all cases, howev...
Administering reirradiation for the treatment of recurrent head and neck cancers is extremely challe...
Radiotherapy (RT) is a definitive treatment option for cancers of the head andneck. Indeed, the most...
Between June 1994 and March 2013, more than 60 clinical trials have been conducted in an attempt to ...
Carbon ion radiotherapy (CIRT) is unique as it possesses well-localized and superior-depth dose dist...
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.Between April...
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.Between April...
Background: Carbon ion radiotherapy showed promising clinical outcomes in 57 patients with bone and ...
Purpose/Objective(s): Prognosis of unresectable high-grade osteosarcoma of the trunk is invariably d...
[Purpose]To evaluate the safety and efficacy of carbon ion radiotherapy (C-ion RT) with 70.4 GyE for...
Carbon ion radiotherapy (CIRT) is a unique radiotherapy, which possesses well localized, and superio...
Carbon ion radiotherapy for bone and soft tissue sarcomas. T. Kamada, R. Imai, H. Tsujii, H. Tsuji, ...
Background and objectives: Osteoradionecrosis (ORN) of maxilla is a serious complication of radiothe...
Purpose To determine the recommend irradiation-dose of carbon ion radiotherapy and to evaluate the s...
Carbon ion radiotherapy (CIRT) is a unique radiotherapy, which possesses well localized and superior...
The first-line treatment for bone and soft-tissue tumors is inevitably surgery. Not all cases, howev...
Administering reirradiation for the treatment of recurrent head and neck cancers is extremely challe...
Radiotherapy (RT) is a definitive treatment option for cancers of the head andneck. Indeed, the most...
Between June 1994 and March 2013, more than 60 clinical trials have been conducted in an attempt to ...
Carbon ion radiotherapy (CIRT) is unique as it possesses well-localized and superior-depth dose dist...
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.Between April...
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.Between April...
Background: Carbon ion radiotherapy showed promising clinical outcomes in 57 patients with bone and ...
Purpose/Objective(s): Prognosis of unresectable high-grade osteosarcoma of the trunk is invariably d...
[Purpose]To evaluate the safety and efficacy of carbon ion radiotherapy (C-ion RT) with 70.4 GyE for...
Carbon ion radiotherapy (CIRT) is a unique radiotherapy, which possesses well localized, and superio...
Carbon ion radiotherapy for bone and soft tissue sarcomas. T. Kamada, R. Imai, H. Tsujii, H. Tsuji, ...